Before Babies Are Born, This Surgeon Operates On Them

The best place for a baby to recover from surgery is the womb. So, when fetuses need surgery, the best place to operate is in utero. Dallas is home to one of the top fetal surgeons in the country, Dr. Timothy Crombleholme, who opened The Fetal Care Center at Medical City Dallas this summer. Shawn Shinneman’s October D Magazine piece chronicles Crombleholme’s path to Dallas, the development of fetal surgery locally, and the story of a North Texas family whose twin children required an operation while they were inside their mother’s womb. The Fetal Care Center is just one of… Full Story

Medical City Plano Adds Single-Dose Radiation For Breast Cancer Patients

A new treatment at Medical City Plano is reducing breast cancer treatment from eight weeks to eight minutes. For early-stage breast cancer patients, the new procedure involves surgery and radiation using iCAD’s Xoft Electronic Brachytherapy System. The FDA-approved treatment uses a miniaturized x-ray to deliver a precise, concentrated dose of radiation to a tumor site directly after surgery, or lumpectomy. The radiation treats the remaining tumor that wasn’t removed during the surgery. The treatment isn’t limited to breast cancer, but can be used for non-melanoma skin cancer and gynecological cancer as well. Worldwide, more than 10,000 patients have been successfully treated.… Full Story

A Health Reporter Has a Tale of a Mystery Fire Alarm During a Theranos-related Reporting Trip

About a year before the Wall Street Journal started a firestorm for then-biotech darling Theranos, one reporter had an experience with the company—which has a Dallas tie through real estate developer Craig Hall, who is an investor—that might’ve warned of the troubles ahead. Kaiser Health News‘ Jenny Gold has a piece out this week about her run in with the company in late 2014, while reporting a story for NPR. After meeting Theranos’ press representatives at Theranos-partner Walgreens, the reps became nervous about the type of questions Gold was asking patients. Gold was curious as to why they all seemed to… Full Story

The State’s CPRIT Program Comes with Risk, But One of Its Top Dogs is Optimistic

Since the state of Texas put $3 billion behind the Cancer Prevention Research Institute of Texas (CPRIT) a decade ago, much of the news coming out has been less than flattering. After lawmakers questioned potential conflicts of interest at the program, state auditors discovered issues with regard to the way a small portion of the grants associated with the $3 billion fund were handed out. Not a good look, to be sure, but the taxpayers who’d originally backed the institute might have found it easier to move past the problems had the news been balanced by, say, the development of… Full Story

Fort Worth Startup Encore Vision to Sell to Pharmaceutical Giant Novartis

Pharmaceutical giant Novartis International is scooping up Fort Worth-based Encore Vision as it aims to introduce the market’s first topical treatment of the eye condition presbyopia.

Novartis, a Swiss public company that raked in $49.4 billion in revenue last year, announced the agreement Tuesday, but did not disclose the financial terms. Full Story

Dallas-Fort Worth Leads Texas in Healthcare Companies on Inc. 5000 List

Eighteen healthcare companies in the Dallas-Fort Worth Metropolitan Area made Inc. magazine’s annual 5,000 list, which attempts to chronicle the fastest growing private companies in the nation. That’s more healthcare companies than any other metropolitan area in Texas, and shows the variety that exist here: Home health, tech, pharmaceutical, provider networks, staffing centers, and services companies. Full Story

Biotech Company Founded In Fort Worth Bought For $2.7 Billion

ZS Pharma launched at the Tech Fort Worth incubator but relocated to California earlier this year. It went public in 2014, hitting the market with a $100 million initial public offering. Now, the Fort Worth Star-Telegram reports, it’s being snapped up by London company AstraZeneca. The daily reports that investors will get $90 a share. ZS Pharma did its early research at the UNT Health Science Center at Fort Worth and received funding from the state of Texas’ Emerging Technology Fund. Full Story